Quicksilver Scientific

Free ground shipping over $50 (excludes HI, AK, & PR)

0

Unsupported Browser

This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

Broad Spectrum Hemp Extract References

  1. Morales P, Hurst DP et al. Molecular Targets of the Phytocannabinoids: A Complex Picture. Prog Chem Org Nat Prod. 2017;103: pp. 103–131.
  2. Pretsch CM, Freyberg J et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomized placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology. 2019 Feb 6 [Epub ahead of print]
  3. Blasco-Benito S, Seijo-Vila M et al. Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer Biochem Pharmacol. 2018 Nov;157: pp. 285-293
  4. Gertsch J, Leonti M et al. Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A. 2008;105(26):pp. 9099–9104
  5. Day J. Botany meets archaeology: people and plants in the past, Journal of Experimental Botany. 2013. (64); 18, pp. 5805–5816,
  6. Naranjo P, Schultes R et al. (Eds) Urgent need for the study of medicinal plants. Ethnobotany: Evolution of a Discipline, Dioscorides Press, Portland, OR (1995), pp. 362-368
  7. Mechoulam, R. (ed.) in Cannabinoids as Therapeutic Agents 1–19 (CRC, Boca Raton, 1986).
  8. Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005;78: pp. 539– 548.
  9. Mechoulam R, Peters M et al. Cannabidiol—recent advances. Chem Biodivers 2007;4: pp. 1678–1692
  10. Premoli M, Aria F et al. Cannabidiol, recent advances and new insights for neuropsychiatric disorders treatment. Life Sciences 224 2019; pp. 120–127
  11. Maccarrone M, Bab I, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015 May; 36(5): pp. 277–296.
  12. Russo EB. Beyond Cannabis: Plants and the Endocannabinoid System. Trends Pharmacol Sci. 2016 Jul;37(7): pp. 594-605
  13. Matsuda LA, Lolait SJ et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346: pp. 561-564
  14. Munro S, Thomas KL et al. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365: pp. 61-65
  15. Járai Z, Wagner J. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A. 1999 Nov 23; 96(24): pp. 14136–14141
  16. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147 Suppl 1(Suppl 1):S163–S171.
  17. Ryberg E, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152:1092–1101.
  18. Glass M, Dragunow M et al. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997 77(2), pp. 299–318.
  19. Brown SM, Wager-Miller J et al. Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochimica et Biophysica Acta, 2002; 1576(3), pp. 255–264
  20. Grotenhermen F. Cannabinoids, Curr. Drug Targets – CNS Neurol. Disord. 2005; (4); pp. 507–530.
  21. Devane WA, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992; 258: pp. 1946–1949
  22. Vaughan CW, Christine MJ. Retrograde signaling by endocannabinoids. Handb Exp Pharmacol. 2005;(168) \: pp. 367-83
  23. Kano M, Ohno-Shosaku T. Retrograde signaling at central synapses via endogenous cannabinoids.Mol Psychiatry. 2002;7(3): pp. 234-5.
  24. Fasinu PS, Phillips S et al. Current status and prospects for cannabidiol preparations as new therapeutic agents, Pharmacotherapy 2016; 36: pp. 781–796
  25. Morales P, Reggio PH et al. An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol, Front. Pharmacol. 2017; (8) p 422
  26. Russo EB, Burnett A et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 2005; 30, pp. 1037–1043
  27. Esposito G, Scuderi C et al. Cannabidiol reduces Ab-induced neuroinflammation and promotes hippocampal neurogenesis through PPARg involvement. PLoS ONE 2011;6:e28668
  28. Bakas T, Devenish S et al. The actions of cannabidiol and 2-arachidonyl glycerol on GABA-A receptors, in Proceedings of the 26th Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Bukovina, 2016; pp. 28
  29. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease–successes and failures. FEBS J. 2013 May;280(9):pp. 1918-43
  30. McPartland JM, Guy GW et al. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One. 2014;9(3):e89566
  31. Di Marzo V, Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci. 2008; 29:229–233.
  32. Melamede, R. 2015, February 24. Dr Robert Melamede PhD on the Endocannabinoid System.  Available at: https://www.youtube.com/watch?v=pvaF1r0HL6Y&app=desktop Accessed April 28, 2019.
  33. Juknat A, Pietr M, Kozela E. et al. Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells. Br J Pharmacol. 2012 Apr;165(8): pp. 2512-28.
  34. Russo EB, Guy GW (2006). A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66: pp. 234–246.
  35. Witkamp R, Meijerink J. The endocannabinoid system: an emerging key player in inflammation. Curr Opin Clin Nutr Metab Care. 2014 Mar;17(2)
  36. Lau BK, Cota D, Cristino L,  et al. Endocannabinoid modulation of homeostatic and non-homeostatic feeding circuits. Neuropharmacology. 2017 Jun 1. pii: S0028-3908(17)30258-7
  37. Malfait AM, Gallily R et al. The non-psychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000;97(17):pp. 9561–6.
  38. Hampson AJ, Grimaldi M et al. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci. 2000;899: pp. 274-82.
  39. Pucci M, Rapino C et al. Epigenetic control of skin differentiation genes by phytocannabinoids.Br J Pharmacol. 2013 Oct;170(3): pp. 581-91
  40. Schmidt E (2010). Production of essential oils. In: Baser KHC, Buchbauer G (eds). Handbook of Essential Oils: Science, Technology, and Applications. CRC Press: Boca Raton, FL, pp. 83–120.
  41. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7): pp. 1344–1364
  42. Study by Quicksilver Scientific. 10 Person intra-absorption comparison of liposomal and non-liposomal cannabidiol.
  43. El-Alfy AT, Ivey K. Antidepressant-like effect of19 -tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol. Biochem. Behav. 2010; 95, pp. 434–442.
  44. Ashton CH, Moore PB et al. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand. 2011 Oct;124(4): pp. 250-61
  45. Babson KA, Sottile J et al. Cannabis, Cannabinoids, and Sleep: a Review of the Literature Curr Psychiatry Rep. 2017 Apr;19(4): pp. 23
  46. Kleiner D, Ditrói K Orv Hetil. The potential use of cannabidiol in the therapy of metabolic syndrome. Orv Hetil. 2012 Apr 1;153(13):pp. 499-504
  47. Fernandez-Ruiz J, Sagredo O et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br. J. Clin. Pharmacol. 2013; 75, pp. 323–333.
  48. Velayudhan L, Van Diepen E et al. Therapeutic potential of cannabinoids in neurodegenerative disorders: a selective review, Curr. Pharmaceut. Des. 2014; 20; pp. 2218–2230
  49. Baul HS, Manikandan C et al. Cannabinoid receptor as a potential therapeutic target for Parkinson’s Disease. Brain Research Bulletin 2019; 146; pp. 244–252
  50. Himadri Shekhaar Baul, Ceera Manikandan, Dwaipayan Sen
  51. Devinsky O, Marsh E et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2015; 15, pp. 270–278.
  52. Baker D, Pryce G et al. The endocannabinoid system and multiple sclerosis, Curr. Pharmaceut. Des. 2008; 14; pp. 2326–2336.
  53. Massi P, Solinas M et al. Cannabidiol as potential anticancer drug. Br. J. Clin. Pharmacol. 2013; 75, pp. 303–312.
  54. Korem N, Zer-Aviv TM et al. Targeting the endocannabinoid system to treat anxiety-related disorders. J Basic Clin Physiol Pharmacol. 2016 May 1;27(3): pp. 193-202.
  55. Blessing EM, Steenkamp MM et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015 Oct; 12(4): pp. 825–836.
  56. Neya LJ, Matthews A et al. Cannabinoid interventions for PTSD: Where to next? Progress in Neuropsychopharmacology & Biological Psychiatry 2019; 93; pp. 124–140
  57. Russo EB. Cannabinoids in the management of difficult to treat pain, Therapeut. Clin. Risk Manag. 2008; 4; pp. 245–259.
  58. S. Peat, Using cannabinoids in pain and palliative care, Int. J. Palliat. Nurs. 2010; 16; pp. 481–485.
  59. Gajofatto A.  Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis, Mult Scler Relat Disord 2016; 8; pp. 64–65.
  60. Sabatino M, Fabiana P et al. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol. 2011 Feb; 162(3): pp. 584–596.
  61. Burstein S.  Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorgan. Med. Chem. 2015; 23, pp. 1377–1385.
  62. Maresz EJ, Carrier ED et al. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli, J. Neurochem. 2005; 95; pp. 437–445.
  63. Kachan V, David P. Cannabinoids and autoimmune diseases: A systematic review. Autoimmunity Reviews 2016; 15; pp.  513–528
  64. Ribeiro A, Almeida V et al. Cannabidiol improves lung function and inflammation in mice submitted to LPS-induced acute lung injury. Immunopharmacol. Immunotoxicol. 2015; 37, pp. 35–41.
  65. McAllister SD, Murase R. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res. 2011; Treat. 129, pp. 37–47.
  66. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?Neuro Endocrinol Lett. 2008 Apr;29(2): pp. 192-200.
  67. Grinspoon, L. A novel approach to the symptomatic treatment of autism. O’Shaughnessy’s, 2010; Summer Issue.
  68. Karhson DS, Krasinska KM et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol Autism. 2018 Mar 12;9: pp. 18.
  69. Borrelli F, Fasolino I. et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem. Pharmacol. 2013; 85, pp. 1306–1316.
  70. Di Carlo G, Izzo AA et al. Cannabinoids for gastrointestinal diseases: potential therapeutic applications, Expet Opin. Invest. Drugs 2003; 12 pp. 39–49.
  71. Merritt JC, Crawford PC et al. Effect of marihuana on intraocular and blood pressure in glaucoma, Ophthalmology 87 1980; pp. 222–228.
  72. El-Remessy AB, Al-Shabrawey M. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes, Am. J. Pathol. 2006; 168; pp. 235–244.
  73. Durst R, Lotan C et al. The potential for clinical use of cannabinoids in treatment of cardiovascular diseases, Cardiovascular Therapeutics 2011; 29; pp. 17–22.
  74. Rajesh M, Mukhopadhyay P et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy, J. Am. Coll. Cardiol. 2010; 56; pp.  2115–2125.
0
Your Cart